Production of radiopharmaceuticals

F-Labeled radiopharmaceuticals have a special advantage for clinical and academic PET studies due to the relatively long half-life of F. The radiotracer can be used for several sequential PET studies of different patients, and it can also be shipped to remote PET centers that do not have a production of radiopharmaceuticals. p F]FDG is already an established tool in the diagnosis of patients with AD. A few F-labeled tracers for serotonin receptors and amyloid plaques have... 

When the box is used for productions of radiopharmaceuticals incorporating a-or P-emitting radionuclides, closed box units without any lead coating may be sufficient. When handling radionuclides with mixed emitting properties, a possibility is to concentrate the shielding to critical parts of the process. This can be done by use of local shielding inside the production unit. However, for aseptic production, one must keep in mind a potential disturbance of the airflow inside the box. 

Bremer, P. O. (1995), Aseptic production of radiopharmaceuticals, in Aseptic Pharmaceutical Manufacturing, Vol. II, Application for the 1990s, Interpharm, Michael J. Groves and Ram Murty, pp. 153-180. 

Hot atom chemical techniques are available in production of radiopharmaceuticals labeled with short-lived positron emitters such as and (Iwata and Wolf 1992). These... 

CPD took the diversification initiated with TRIUMF a step further in 1978, when it decided to move into production of radiopharmaceuticals (known as labelled or ta ed isotopes in the early days of CPD). For years CPD had supphed bulk isotopes to pharmaceutical companies. Now it decided that processing radioisotopes into compounds ready for medical use oflFered an opportunity for growth and profit that it could no longer ignore. The production of radiopharmaceuticals required more precision and stricter quality controls than the manufacture ofbulk isotopes, so in 1980 the isotopes branch created a special group to develop these products. 

---